GlassScriptPhysician profile
Amy D Meusborn
NPI 1962630871
$3,546.94
in general payments reported to CMS, 2019-2025
29 companies · $643 in 2025
The $643 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $594 · 2022: $687 · 2023: $840 · 2024: $783 · 2025: $643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,024 · Education: $242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,023.83 |
| Education | $242.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $685.06 | 2021-2024 | Xtandi |
| Sumitomo Pharma America, INC. | $516.46 | 2023-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $362.67 | 2021-2025 | Erleada, Akeega, Carvykti |
| Abbvie INC. | $328.45 | 2021-2025 | |
| Urovant Sciences INC | $240.40 | 2021-2022 | |
| Pfizer INC. | $230.94 | 2021-2025 | |
| 180 Medical, INC. | $163.22 | 2021-2025 | |
| Boston Scientific Corporation | $153.16 | 2021-2025 | Upsylon, Greenlight Xps, Ams 700 |
| Progenics Pharmaceuticals, INC. | $127.89 | 2021-2024 | Pylarify |
| Allergan, INC. | $80.77 | 2021-2022 | |
| Axonics, INC. | $67.46 | 2023-2024 | Bulkamid, Axonics |
| Endo Pharmaceuticals INC. | $59.21 | 2022-2023 | Xiaflex |
| Tolmar, INC. | $56.43 | 2023-2025 | Jatenzo |
| Teleflex LLC | $52.75 | 2021-2025 | Urolift |
| Merck Sharp & Dohme LLC | $45.77 | 2022-2025 | Keytruda, Lynparza |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $41.99 | 2023-2025 | Jelmyto |
| Blue Earth Diagnostics | $38.67 | 2021-2022 | |
| Antares Pharma, INC. | $34.50 | 2023 | Tlando, Xyosted, Nocdurna |
| Novartis Pharmaceuticals Corporation | $34.45 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $33.88 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.25 | 2021-2022 | |
| Coloplast Corp | $28.44 | 2021-2023 | Speedicath |
| Procept Biorobotics Corporation | $27.67 | 2023 | Aquabeam Robotic System |
| Tolmar Pharmaceuticals, INC. | $19.98 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.94 | 2025 | Eohilia |
| Calyxo, INC. | $18.32 | 2024 | Cvac Aspiration System |
| Photocure INC | $16.34 | 2024 | Cysview |
| Rochester Medical Corporation | $16.05 | 2021 | |
| Myovant Sciences INC. | $14.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Meusborn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.